Last reviewed · How we verify
Namenda
At a glance
| Generic name | Namenda |
|---|---|
| Also known as | Memantine |
| Sponsor | Inova Health Care Services |
| Target | Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 3A, Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Moderate to Severe Alzheimer's Type Dementia
Common side effects
- Headache
- Dizziness
- Diarrhea
- Hypertension
- Anxiety
- Influenza
- Constipation
- Somnolence
- Weight increased
- Back pain
- Depression
- Abdominal pain
Serious adverse events
- Seizure
- Agranulocytosis
- Leukopenia
- Pancytopenia
- Thrombocytopenia
- Thrombotic thrombocytopenic purpura
- Cardiac failure congestive
- Pancreatitis
- Hepatitis
- Stevens Johnson syndrome
Key clinical trials
- Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain (PHASE2)
- Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial (PHASE2, PHASE3)
- Pattern Separation in Major Depressive Disorder (PHASE1)
- Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD) (EARLY_PHASE1)
- Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions (PHASE3)
- Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial) (PHASE2)
- Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease (PHASE4)
- Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |